- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma
July 20th 2024, 6:14pm
International Congress on the Future of Breast Cancer East
Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.
Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer
July 20th 2024, 12:20am
International Congress on the Future of Breast Cancer East
Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.
AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer
July 19th 2024, 11:29pm
International Congress on the Future of Breast Cancer East
Hope Rugo, MD, discusses the management of treatment-limiting toxicities in breast cancer, including the use of antibody-drug conjugates and immunotherapy.
Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer
July 19th 2024, 9:42pm
International Congress on the Future of Breast Cancer East
Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.
ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers
July 16th 2024, 5:47pm
This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.
Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups
July 12th 2024, 9:29pm
Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.
Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma
July 12th 2024, 9:11pm
Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.
Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC
July 12th 2024, 9:10pm
Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.
Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC
July 12th 2024, 8:58pm
Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.
Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC
July 12th 2024, 8:55pm
Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.
Dr McGregor on the Data for Abemaciclib in Advanced ccRCC
July 12th 2024, 8:47pm
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.
Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes
July 12th 2024, 7:08pm
Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.
No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC
July 12th 2024, 5:24pm
Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.
Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC
July 11th 2024, 11:30pm
Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.
Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations
July 11th 2024, 11:21pm
Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.
Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC
July 11th 2024, 9:15pm
Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.
Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC
July 11th 2024, 8:49pm
Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.
REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer
July 8th 2024, 12:00pm
ESMO Gastrointestinal Cancers Congress
Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
July 3rd 2024, 6:00pm
ESMO Gynecological Cancers Congress
Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
July 2nd 2024, 8:55pm
ESMO Gastrointestinal Cancers Congress
Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.